Lineage Cell Therapeutics, Inc. (LCTX) Current Ratio
- Current ratio · latest quarter: Value 6.61×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 6.61× | Current assets / current liabilities. $52.97M ÷ $8.02M ≈ 6.61× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 52.97M USD | Assets, Current |
| Current obligations | 8.02M USD | Liabilities, Current |
| Cash and equivalents | 37.35M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 13.47M USD | Marketable Securities, Current |
| Customer receivables | 790.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | Inventory, Net |
| Payables | 1.54M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $52.97M | $8.02M | $37.35M | $13.47M | $790.00K | (m) | $1.54M | (m) | 6.61× |
| 2026-03-31 | $56.16M | $8.15M | $35.94M | $17.44M | $806.00K | (m) | $1.59M | (m) | 6.89× |
| 2025-12-31 | $59.16M | $11.37M | $40.79M | $14.99M | $891.00K | (m) | $2.34M | (m) | 5.20× |
| 2025-09-30 | $42.26M | $9.38M | $40.46M | $23.00K | $127.00K | (m) | $1.52M | (m) | 4.50× |
| 2025-06-30 | $43.84M | $10.76M | $42.27M | $17.00K | $256.00K | (m) | $1.50M | (m) | 4.08× |
| 2025-03-31 | $49.98M | $13.09M | $47.89M | $19.00K | $213.00K | (m) | $2.00M | (m) | 3.82× |
| 2024-12-31 | $51.00M | $13.98M | $45.79M | $2.02M | $638.00K | (m) | $1.17M | (m) | 3.65× |
| 2024-09-30 | $34.40M | $13.86M | $27.75M | $4.96M | $405.00K | (m) | $1.60M | (m) | 2.48× |
| 2024-06-30 | $40.39M | $15.28M | $29.62M | $8.87M | $235.00K | (m) | $2.39M | (m) | 2.64× |
| 2024-03-31 | $45.72M | $16.89M | $43.58M | $45.00K | $77.00K | (m) | $2.21M | (m) | 2.71× |
| 2023-12-31 | $38.44M | $17.96M | $35.44M | $50.00K | $745.00K | (m) | $2.05M | (m) | 2.14× |
| 2023-09-30 | $43.48M | $15.88M | $31.47M | $9.86M | $432.00K | (m) | $2.43M | (m) | 2.74× |
| 2023-06-30 | $48.49M | $16.05M | $33.89M | $12.04M | $443.00K | (m) | $2.19M | (m) | 3.02× |
| 2023-03-31 | $49.66M | $17.23M | $15.45M | $31.36M | (m) | (m) | $3.00M | (m) | 2.88× |
| 2022-12-31 | $60.00M | $18.98M | $11.36M | $46.52M | $297.00K | (m) | $2.39M | (m) | 3.16× |
| 2022-09-30 | $68.51M | $22.74M | $24.75M | $41.60M | $400.00K | (m) | $2.87M | (m) | 3.01× |
| 2022-06-30 | $74.03M | $25.09M | $70.86M | $1.17M | $500.00K | (m) | $2.59M | (m) | 2.95× |
| 2022-03-31 | $81.87M | $24.59M | $78.06M | $1.88M | (m) | (m) | $2.96M | (m) | 3.33× |
| 2021-12-31 | $111.55M | $47.12M | $55.74M | $2.62M | (m) | (m) | $3.54M | (m) | 2.37× |
| 2021-09-30 | $68.34M | $8.79M | $60.81M | $4.29M | (m) | (m) | $3.46M | (m) | 7.77× |
| 2021-06-30 | $71.58M | $6.77M | $62.00M | $6.75M | (m) | (m) | $2.72M | (m) | 10.58× |
| 2021-03-31 | $64.62M | $6.62M | $56.21M | $6.15M | (m) | (m) | $2.80M | (m) | 9.76× |
| 2020-12-31 | $44.00M | $7.77M | $32.59M | $8.98M | (m) | (m) | $2.61M | (m) | 5.66× |
| 2020-09-30 | $39.74M | $7.75M | $32.56M | $5.48M | (m) | (m) | $3.15M | (m) | 5.13× |
| 2020-06-30 | $46.20M | $7.52M | $12.68M | $7.58M | (m) | (m) | $3.42M | (m) | 6.14× |
| 2020-03-31 | $52.28M | $6.97M | $9.83M | $15.93M | (m) | (m) | $3.52M | (m) | 7.50× |
| 2019-12-31 | $57.52M | $6.49M | $9.50M | $21.22M | (m) | (m) | $2.43M | (m) | 8.86× |
| 2019-09-30 | $61.59M | $6.16M | $14.37M | $21.32M | (m) | (m) | $2.01M | (m) | 9.99× |
| 2019-06-30 | $20.46M | $7.86M | $8.21M | $8.48M | (m) | (m) | $2.78M | (m) | 2.60× |
| 2019-03-31 | $30.66M | $8.72M | $18.01M | $9.09M | (m) | (m) | $1.38M | (m) | 3.51× |
| 2018-12-31 | $36.36M | $6.81M | $23.59M | $7.15M | $51.00K | (m) | $2.36M | (m) | 5.34× |
| 2018-09-30 | $36.91M | $4.50M | $19.47M | $1.97M | (m) | (m) | $717.00K | (m) | 8.20× |
| 2018-06-30 | $34.49M | $5.84M | $27.21M | $1.95M | (m) | (m) | $1.18M | (m) | 5.90× |
| 2018-03-31 | $36.13M | $5.81M | $29.83M | (m) | (m) | (m) | $703.00K | (m) | 6.22× |
| 2017-12-31 | $42.62M | $6.88M | $36.84M | $1.34M | $139.00K | (m) | $938.00K | (m) | 6.20× |
| 2017-09-30 | $23.23M | $6.01M | $16.66M | (m) | (m) | (m) | $508.00K | (m) | 3.86× |
| 2017-06-30 | $25.52M | $13.53M | $14.55M | (m) | (m) | (m) | $752.00K | (m) | 1.89× |
| 2017-03-31 | $29.26M | $8.82M | $23.82M | (m) | (m) | (m) | $1.06M | (m) | 3.32× |
| 2016-12-31 | $25.65M | $8.85M | $22.09M | (m) | $344.00K | (m) | $1.59M | (m) | 2.90× |
| 2016-09-30 | $35.15M | $8.34M | $30.45M | (m) | (m) | (m) | $1.69M | (m) | 4.22× |
| 2016-06-30 | $31.05M | $7.40M | $27.70M | (m) | (m) | (m) | $1.76M | (m) | 4.19× |
| 2016-03-31 | $32.91M | $13.67M | $27.13M | (m) | (m) | (m) | $4.55M | (m) | 2.41× |
| 2015-12-31 | $47.24M | $12.46M | $42.23M | (m) | $754.00K | (m) | $2.80M | (m) | 3.79× |
| 2015-09-30 | $34.37M | $10.34M | $29.38M | (m) | $664.00K | $260.00K | $1.93M | (m) | 3.32× |
| 2015-06-30 | $37.00M | $9.19M | $31.46M | (m) | $545.00K | $297.00K | $2.66M | (m) | 4.03× |
| 2015-03-31 | $28.54M | $8.20M | $25.83M | (m) | $605.80K | $299.31K | $2.71M | (m) | 3.48× |
| 2014-12-31 | $32.41M | $7.07M | $29.49M | (m) | $549.00K | $266.00K | $2.30M | (m) | 4.58× |
| 2014-09-30 | $9.94M | $5.79M | $7.42M | (m) | $662.00K | $253.57K | $2.42M | (m) | 1.72× |
| 2014-06-30 | $18.65M | $5.07M | $15.72M | (m) | $612.90K | $257.93K | $1.88M | (m) | 3.68× |
| 2014-03-31 | $9.25M | $5.62M | $6.64M | (m) | $600.40K | $236.59K | $2.53M | (m) | 1.65× |
| 2013-12-31 | $7.95M | $6.96M | $5.50M | (m) | $575.90K | $178.69K | $3.43M | (m) | 1.14× |
| 2013-09-30 | $8.68M | $4.60M | $6.72M | (m) | $461.00K | $61.13K | $2.20M | (m) | 1.89× |
| 2013-06-30 | $18.13M | $4.43M | $14.31M | (m) | $420.00K | $64.75K | $1.69M | (m) | 4.09× |
| 2013-03-31 | $12.97M | $4.30M | $9.90M | (m) | $478.00K | $52.34K | $1.46M | (m) | 3.02× |
| 2012-12-31 | $7.18M | $4.39M | $4.35M | (m) | $395.00K | $55.32K | $1.17M | (m) | 1.64× |
| 2012-09-30 | $9.75M | $2.57M | $7.83M | (m) | $891.00K | $56.97K | $708.96K | (m) | 3.79× |
| 2012-06-30 | $14.61M | $2.96M | $12.66M | (m) | $574.00K | $55.02K | $890.88K | (m) | 4.93× |
| 2012-03-31 | $18.64M | $1.97M | $16.49M | (m) | (m) | $54.87K | (m) | (m) | 9.49× |
| 2011-12-31 | $24.96M | $3.15M | $22.21M | (m) | $353.00K | $51.17K | $1.12M | (m) | 7.93× |
| 2011-09-30 | $28.56M | $2.72M | $26.23M | (m) | (m) | $61.12K | (m) | (m) | 10.49× |
| 2011-06-30 | $29.42M | $3.29M | $27.38M | (m) | (m) | $56.84K | (m) | (m) | 8.95× |
| 2010-12-31 | $35.57M | $2.48M | $33.32M | (m) | (m) | $45.47K | (m) | (m) | 14.34× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |